Search

Yusho, occurred in 1968, is an intoxication of high concentrations of polychlorinated dibenzofurans and their related compounds. Like other intoxication by dioxin-like compounds, one of the major symptoms of Yusho is skin symptom such as chloracne and pigmentation. Dioxins exert their major toxicity by binding and activating aryl hydrocarbon receptor (AHR) and subsequent generation of reactive oxygen species (ROS). Sustained and exaggerated AHR activation by dioxins accelerates the keratinization of keratinocytes and converts the sebaceous differentiation of sebocytes to keratinocyte-like differentiation which results in loss of sebocytes and cyst formation of hair follicle, leading to chloracne. AHR activation by dioxins upregulates the melanogenesis of melanocytes, leading to pigmentation. Phytochemical Kampo drugs which inhibit AHR activation and subsequent ROS production are potential treatment for Yusho patients.

Traditional herbal (Kampo) medicine for the treatment of rheumatoid arthritis (RA) has not been evaluated for changes in immune status during its use, although several anti-inflammatory effects have been studied in vitro. In this case report, we describe a 32-year-old Japanese female with RA who was effectively treated with the Kampo medicine, Hochu-ekki to (Bu-Zhong-Yi-Qi-Tang, 補中益気湯) . This treatment decreased the serum concentration of soluble CD23 (sCD23) and RA activity, in addition to tumor necrosis factor-α. These findings suggest that the therapeutic action of herbal medicine might be attributable to suppression of B cell activation. 和漢薬治療は慢性関節リウマチ(RA)に対して極めて有用な治療法であるが,その作用機序に関しては,In Vitroによる生薬の抗炎症効果は解析されているものの,In Vivoでの免疫学的な評価はいまだ未着手な部分が多い。われわれは補中益気湯などが有効であったRAの一例を経験した。この患者は,RAの疾患活動性の低下に加えて血清中可溶性CD23(sCD23)が低下し,さらに,血清TNF-α濃度も,漸次低下していた。このことからRAの治療において和漢薬は単に抗炎症効果を有するだけでなくImmunomodulatorとして作用している可能性が示唆された。その一部としてRA患者でのB細胞の活性化を抑制している可能性がある。

1)非細菌性前立腺炎および前立腺炎様症候群における肛門疾患合併率は29.7%, 活動性病変合併率は15.4%であり, 他の泌尿器科疾患での合併率に比し有意に高い.2)合併肛門疾患では痔疾患とくに痔核の合併頻度が高い.3)治療による臨床的有効率は非細菌性前立腺炎が71.4%, 前立腺炎様症候群が58.2%であった.4)前立腺炎と痔疾患とくに痔核の合併および発症とは深い関係がある.肛門疾患を合併する前立腺炎に対して桂枝茯苓丸は有用であった, We analyzed the incidence of anal disease in patients with nonbacterial prostatitis (NBP) or with prostatitis-like syndrome (PLS), and evaluated the clinical efficacy. The complicated rate of anal disease in these patients was 29.7% (31.8% for NBP and 28.1% for PLS), and the overall incidence of active anal disease was 15.4% (16.2% for NBP and 14.8% for PLS), it yielded a significantly higher complicated rate than other urological disease (p less than 0.01). The most common type of anal disease was hemorrhoids, especially piles. The clinical cure rate for anal disease in NBP patients was 71.4%, and in PLS patients was 58.2%. The high incidence of hemorrhoids (especially piles) was in these patients by clinico-statistical observation suggests that the development of anal disease may be etiologically correlated with NBP and PLS. Furthermore, we noted that Kampo treatment (Keisibukuryogan) was useful in the treatment of prostatitis complicated by anal disease, especially when combined with anti-hemorrhoidal suppositories against active anal disease in PLS patients (p less than 0.05).

西洋医学治療の結果, 難治・再発した慢性非細菌性前立腺炎と前立腺炎様症候群の症例に対し漢方療法を試みた.1)漢方療法の臨床効果は, 慢性非細菌性前立腺炎61例では著効率21.3%, 臨床的有効率67.2%であり, 前立腺炎様症候群82例では著効率19.5%, 臨床的有効率52.4%であった.2)漢方単独療法と西洋薬併用治療群の効果を比較すると, 前立腺炎様症候群では両群間に差はないが, 慢性非細菌性前立腺炎では漢方単独群より抗菌剤併用群の方が効果が優れていた(p, Kampo treatment was attempted in cases of chronic nonbacterial prostatitis and prostatitis-like syndrome which was intractable or recurred when treated with western medicine. The clinical effects of Kampo treatment were excellent in 21.3% with an efficacy rate of 67.2% for the cases with chronic non-bacterial prostatitis, and excellent in 19.5% with an efficacy rate of 52.4% in the cases with prostatitis-like syndrome. When the clinical effects were compared with those of western therapy performed in the cases which had recurrence, Kampo treatment showed more excellent effects (p less than 0.1) for both types of disease, and the treatment with Chinese medicine was suggested useful. In a comparison of the effects between the cases given only Kampo treatment and those given both Kampo treatment and western treatment using anti-inflammatory agents, no difference was seen in the cases with the prostatitis-like syndrome, but in the cases with chronic non-bacterial prostatitis, the effects were better in the concomitant treatment group than in the group given only Kampo treatment (p less than 0.1). The response to the Kampo treatment differed depending on the type of disease. Among the antibacterial agents used concomitantly in the cases of chronic non-bacterial prostatitis, new-quinolones showed better results than ST compounds or tetracyclines, but no statistically significant differences were seen among the drugs. Of the Kampo drugs used, Keisibukuryogan and Simotuto showed high clinical usefulness in both types of disease and there was no statistically significant difference among the other drugs. The incidence rate of side effects (Goji) due to Kampo treatment was 6.3% and was higher in patients administered Keisibukuryogan.

We analyzed the incidence of anal disease in patients with nonbacterial prostatitis (NBP) or with prostatitis-like syndrome (PLS), and evaluated the clinical efficacy. The complicated rate of anal disease in these patients was 29.7% (31.8% for NBP and 28.1% for PLS), and the overall incidence of active anal disease was 15.4% (16.2% for NBP and 14.8% for PLS), it yielded a significantly higher complicated rate than other urological disease (p less than 0.01). The most common type of anal disease was hemorrhoids, especially piles. The clinical cure rate for anal disease in NBP patients was 71.4%, and in PLS patients was 58.2%. The high incidence of hemorrhoids (especially piles) was in these patients by clinico-statistical observation suggests that the development of anal disease may be etiologically correlated with NBP and PLS. Furthermore, we noted that Kampo treatment (Keisibukuryogan) was useful in the treatment of prostatitis complicated by anal disease, especially when combined with anti-hemorrhoidal suppositories against active anal disease in PLS patients (p less than 0.05).

Kampo treatment was attempted in cases of chronic nonbacterial prostatitis and prostatitis-like syndrome which was intractable or recurred when treated with western medicine. The clinical effects of Kampo treatment were excellent in 21.3% with an efficacy rate of 67.2% for the cases with chronic non-bacterial prostatitis, and excellent in 19.5% with an efficacy rate of 52.4% in the cases with prostatitis-like syndrome. When the clinical effects were compared with those of western therapy performed in the cases which had recurrence, Kampo treatment showed more excellent effects (p less than 0.1) for both types of disease, and the treatment with Chinese medicine was suggested useful. In a comparison of the effects between the cases given only Kampo treatment and those given both Kampo treatment and western treatment using anti-inflammatory agents, no difference was seen in the cases with the prostatitis-like syndrome, but in the cases with chronic non-bacterial prostatitis, the effects were better in the concomitant treatment group than in the group given only Kampo treatment (p less than 0.1). The response to the Kampo treatment differed depending on the type of disease. Among the antibacterial agents used concomitantly in the cases of chronic non-bacterial prostatitis, new-quinolones showed better results than ST compounds or tetracyclines, but no statistically significant differences were seen among the drugs. Of the Kampo drugs used, Keisibukuryogan and Simotuto showed high clinical usefulness in both types of disease and there was no statistically significant difference among the other drugs. The incidence rate of side effects (Goji) due to Kampo treatment was 6.3% and was higher in patients administered Keisibukuryogan.